April 10, 2026
RFK Jr. Announces 14 Peptides Coming Off FDA Restricted List
In a landmark announcement on February 27, 2026, HHS Secretary Robert F. Kennedy Jr. stated that approximately 14 of the 19 peptides currently on the FDA’s Category 2 “do not compound” list would be reclassified — making them eligible for legal compounding through licensed pharmacies once again.
The announcement, made on the Joe Rogan Experience podcast, represents the single largest reversal of peptide restrictions in U.S. regulatory history.
Background: The 2023 FDA Peptide Ban
In late 2023, the FDA placed numerous research peptides on a restricted compounding list, citing safety concerns and lack of clinical trial data. The move affected some of the most widely researched compounds in the longevity, recovery, and metabolic health space — including BPC-157, TB-500, CJC-1295, and others.
What RFK Jr. Announced
Kennedy indicated that approximately 14 of the 19 restricted peptides would move from Category 2 to Category 1, restoring their eligibility for licensed compounding pharmacies. Compounds expected to be affected include:
Important Caveats
As of publication, no formal FDA rule change has been published in the Federal Register. Kennedy’s announcement was made through a media appearance, not an official regulatory filing. Researchers should continue to monitor FDA official communications for formal guidance.
This article is for educational and informational purposes only. Nothing constitutes medical or legal advice. Always verify current legal status with a licensed healthcare provider.